DexCom Inc
Chiusa
SettoreSettore sanitario
69.73 1.19
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
68.85
Massimo
71.01
Entrata | -68M 200M |
|---|---|
Vendite | -68M 1.2B |
P/E Media del settore | 29.644 50.958 |
EPS | 0.56 |
Margine di Profitto | 16.738 |
Dipendenti | 11,000 |
EBITDA | -52M 337M |
Raccomandazioni | Fortemente da comprare |
|---|---|
Previsioni per 12 mesi | +19.86% upside |
Utili prossimi | 29 lug 2026 |
|---|
Capitalizzazione di Mercato | 3B 27B |
|---|---|
Apertura precedente | 68.54 |
Chiusura precedente | 69.73 |
Notizie sul Sentiment di mercato
By Acuity
18%
82%
35 / 342 Classifica in Healthcare
DexCom Inc Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Chi Siamo DexCom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.